A digital neuroscience company has announced a new £500,000 contract with a major pharmaceutical company for the use of its Cognition Kit digital health software in a clinical trial.
Cambridge Cognition, which provides cognitive assessment software for academic research and healthcare provision, will provide their Cognitive Kit software as part of a clinical trial.
“The pharmaceutical industry is increasingly looking to develop novel biomarkers and use digital phenotyping techniques to improve their data intelligence and market access,” said Chief executive Steven Powell.
“Having successfully demonstrated the effectiveness of Cognition Kit technology through our ongoing partnership with Takeda, we are delighted to be signing additional clients with whom we expect to establish long-lasting commercial partnerships.”
The clinical trial will use a Cognition Kit smartphone app to test brain health remotely and frequently, providing the sponsor with rich real-world data outside of clinical sites in a more holistic, cost-effective and patient-centric fashion.
Researchers use the data gathered by the devices to make more insightful treatment decisions for their patients.